Cargando…

Delayed NLRP3 inflammasome inhibition ameliorates subacute stroke progression in mice

BACKGROUND: Ischemic stroke immediately evokes a strong neuro-inflammatory response within the vascular compartment, which contributes to primary infarct development under vessel occlusion as well as further infarct growth despite recanalization, referred to as ischemia/reperfusion injury. Later, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellut, Maximilian, Bieber, Michael, Kraft, Peter, Weber, Alexander N. R., Stoll, Guido, Schuhmann, Michael K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811791/
https://www.ncbi.nlm.nih.gov/pubmed/36600259
http://dx.doi.org/10.1186/s12974-022-02674-w
_version_ 1784863599962882048
author Bellut, Maximilian
Bieber, Michael
Kraft, Peter
Weber, Alexander N. R.
Stoll, Guido
Schuhmann, Michael K.
author_facet Bellut, Maximilian
Bieber, Michael
Kraft, Peter
Weber, Alexander N. R.
Stoll, Guido
Schuhmann, Michael K.
author_sort Bellut, Maximilian
collection PubMed
description BACKGROUND: Ischemic stroke immediately evokes a strong neuro-inflammatory response within the vascular compartment, which contributes to primary infarct development under vessel occlusion as well as further infarct growth despite recanalization, referred to as ischemia/reperfusion injury. Later, in the subacute phase of stroke (beyond day 1 after recanalization), further inflammatory processes within the brain parenchyma follow. Whether this second wave of parenchymal inflammation contributes to an additional/secondary increase in infarct volumes and bears the potential to be pharmacologically targeted remains elusive. We addressed the role of the NLR-family pyrin domain-containing protein 3 (NLRP3) inflammasome in the subacute phase of ischemic stroke. METHODS: Focal cerebral ischemia was induced in C57Bl/6 mice by a 30-min transient middle cerebral artery occlusion (tMCAO). Animals were treated with the NLRP3 inhibitor MCC950 therapeutically 24 h after or prophylactically before tMCAO. Stroke outcome, including infarct size and functional deficits as well as the local inflammatory response, was assessed on day 7 after tMCAO. RESULTS: Infarct sizes on day 7 after tMCAO decreased about 35% after delayed and about 60% after prophylactic NLRP3 inhibition compared to vehicle. Functionally, pharmacological inhibition of NLRP3 mitigated the local inflammatory response in the ischemic brain as indicated by reduction of infiltrating immune cells and reactive astrogliosis. CONCLUSIONS: Our results demonstrate that the NLRP3 inflammasome continues to drive neuroinflammation within the subacute stroke phase. NLRP3 inflammasome inhibition leads to a better long-term outcome—even when administered with a delay of 1 day after stroke induction, indicating ongoing inflammation-driven infarct progression. These findings may pave the way for eagerly awaited delayed treatment options in ischemic stroke. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-022-02674-w.
format Online
Article
Text
id pubmed-9811791
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98117912023-01-05 Delayed NLRP3 inflammasome inhibition ameliorates subacute stroke progression in mice Bellut, Maximilian Bieber, Michael Kraft, Peter Weber, Alexander N. R. Stoll, Guido Schuhmann, Michael K. J Neuroinflammation Research BACKGROUND: Ischemic stroke immediately evokes a strong neuro-inflammatory response within the vascular compartment, which contributes to primary infarct development under vessel occlusion as well as further infarct growth despite recanalization, referred to as ischemia/reperfusion injury. Later, in the subacute phase of stroke (beyond day 1 after recanalization), further inflammatory processes within the brain parenchyma follow. Whether this second wave of parenchymal inflammation contributes to an additional/secondary increase in infarct volumes and bears the potential to be pharmacologically targeted remains elusive. We addressed the role of the NLR-family pyrin domain-containing protein 3 (NLRP3) inflammasome in the subacute phase of ischemic stroke. METHODS: Focal cerebral ischemia was induced in C57Bl/6 mice by a 30-min transient middle cerebral artery occlusion (tMCAO). Animals were treated with the NLRP3 inhibitor MCC950 therapeutically 24 h after or prophylactically before tMCAO. Stroke outcome, including infarct size and functional deficits as well as the local inflammatory response, was assessed on day 7 after tMCAO. RESULTS: Infarct sizes on day 7 after tMCAO decreased about 35% after delayed and about 60% after prophylactic NLRP3 inhibition compared to vehicle. Functionally, pharmacological inhibition of NLRP3 mitigated the local inflammatory response in the ischemic brain as indicated by reduction of infiltrating immune cells and reactive astrogliosis. CONCLUSIONS: Our results demonstrate that the NLRP3 inflammasome continues to drive neuroinflammation within the subacute stroke phase. NLRP3 inflammasome inhibition leads to a better long-term outcome—even when administered with a delay of 1 day after stroke induction, indicating ongoing inflammation-driven infarct progression. These findings may pave the way for eagerly awaited delayed treatment options in ischemic stroke. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-022-02674-w. BioMed Central 2023-01-04 /pmc/articles/PMC9811791/ /pubmed/36600259 http://dx.doi.org/10.1186/s12974-022-02674-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bellut, Maximilian
Bieber, Michael
Kraft, Peter
Weber, Alexander N. R.
Stoll, Guido
Schuhmann, Michael K.
Delayed NLRP3 inflammasome inhibition ameliorates subacute stroke progression in mice
title Delayed NLRP3 inflammasome inhibition ameliorates subacute stroke progression in mice
title_full Delayed NLRP3 inflammasome inhibition ameliorates subacute stroke progression in mice
title_fullStr Delayed NLRP3 inflammasome inhibition ameliorates subacute stroke progression in mice
title_full_unstemmed Delayed NLRP3 inflammasome inhibition ameliorates subacute stroke progression in mice
title_short Delayed NLRP3 inflammasome inhibition ameliorates subacute stroke progression in mice
title_sort delayed nlrp3 inflammasome inhibition ameliorates subacute stroke progression in mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811791/
https://www.ncbi.nlm.nih.gov/pubmed/36600259
http://dx.doi.org/10.1186/s12974-022-02674-w
work_keys_str_mv AT bellutmaximilian delayednlrp3inflammasomeinhibitionamelioratessubacutestrokeprogressioninmice
AT biebermichael delayednlrp3inflammasomeinhibitionamelioratessubacutestrokeprogressioninmice
AT kraftpeter delayednlrp3inflammasomeinhibitionamelioratessubacutestrokeprogressioninmice
AT weberalexandernr delayednlrp3inflammasomeinhibitionamelioratessubacutestrokeprogressioninmice
AT stollguido delayednlrp3inflammasomeinhibitionamelioratessubacutestrokeprogressioninmice
AT schuhmannmichaelk delayednlrp3inflammasomeinhibitionamelioratessubacutestrokeprogressioninmice